Bremer E - Search Results

1

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W. Bremer E, et al. Cancer Res. 2008 Jan 15;68(2):597-604. doi: 10.1158/0008-5472.CAN-07-5171. Cancer Res. 2008. PMID: 18199557

2

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Bremer E, et al. Int J Cancer. 2004 Mar 20;109(2):281-90. doi: 10.1002/ijc.11702. Int J Cancer. 2004. PMID: 14750182 Free article.

3

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.

Bremer E, Samplonius D, Kroesen BJ, van Genne L, de Leij L, Helfrich W. Bremer E, et al. Neoplasia. 2004 Sep-Oct;6(5):636-45. doi: 10.1593/neo.04229. Neoplasia. 2004. PMID: 15548373 Free PMC article.

4

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.

Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W. Bremer E, et al. J Biol Chem. 2005 Mar 18;280(11):10025-33. doi: 10.1074/jbc.M413673200. Epub 2005 Jan 11. J Biol Chem. 2005. PMID: 15644326 Free article.

5

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W. Bremer E, et al. Cancer Res. 2005 Apr 15;65(8):3380-8. doi: 10.1158/0008-5472.CAN-04-2756. Cancer Res. 2005. PMID: 15833872

6

CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.

Bremer E, ten Cate B, Samplonius DF, de Leij LF, Helfrich W. Bremer E, et al. Blood. 2006 Apr 1;107(7):2863-70. doi: 10.1182/blood-2005-07-2929. Epub 2005 Dec 6. Blood. 2006. PMID: 16332967 Free article.

7

Targeted induction of apoptosis for cancer therapy: current progress and prospects.

Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W. Bremer E, et al. Trends Mol Med. 2006 Aug;12(8):382-93. doi: 10.1016/j.molmed.2006.06.002. Epub 2006 Jun 23. Trends Mol Med. 2006. PMID: 16798087 Review.

8

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.

ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. ten Cate B, et al. Among authors: bremer e. Leukemia. 2007 Feb;21(2):248-52. doi: 10.1038/sj.leu.2404477. Epub 2006 Nov 23. Leukemia. 2007. PMID: 17122863

9

Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapy.

Bremer E, Helfrich W. Bremer E, et al. Discov Med. 2006 Jun;6(33):113-7. Discov Med. 2006. PMID: 17234145 Free article.

10

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W. Stieglmaier J, et al. Among authors: bremer e. Cancer Immunol Immunother. 2008 Feb;57(2):233-46. doi: 10.1007/s00262-007-0370-8. Epub 2007 Jul 31. Cancer Immunol Immunother. 2008. PMID: 17665197 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

386 results

Search Page